|
||||||||
Company Profile | ||||||||
Chairman | CEO | Spokesperson | Tel | Address | Date of Listing (Regular) | |||
---|---|---|---|---|---|---|---|---|
LIN ,YUNG- HSIANG | LIN ,YUNG- HSIANG | Mandy Huang | (02)8797-7811 | 8F, NO.187 Kang Chien Rd.,Taipei , Taiwan R.O.C | 2013/09/12 | |||
Industry | Main Business | |||||||
Biotechnology and Medical Care | TCI is an integrated bio-science company dedicated in manufacturing food supplement and skin care product. With a steady focus on innovation, TCI has created various types of food supplement including capsule, tablet, functional beverage, and sachet, as long as multiple forms of skin care product such as oil-type, cream-type, mousse-type, facial mask, and etc. TCI believes entrepreneurial success starts with customer value. By integrating R&D capability with market demand, TCI commits to provide the end-to-end service, from product design to product delivery,to all our global customers. Considering the growth of global demand on food supplement, TCI fastens his step at exploring the global market with emphasis the China market within the next 5 years. Along with the new expansion of factories in Shanghai and Pingtong, TCI will establish a strong stand in food supplement industry and become the leading ODM manufacturers in the world. |
Market Information ( 2024/03/29 ) | |||||||||||
Shr. Vol. | Highest | Lowest | Closed | Change | Transaction | TurnOver(%) | long margin balance (1,000shr.) |
Short margin balance (1,000shr.) |
|||
---|---|---|---|---|---|---|---|---|---|---|---|
171.559 | 155.50 | 153.50 | 154.50 | -1.00 | 259 | .00 | 1,807 | 4 | |||
Trading method | Fun purchase price or securities pneeded on T day |
Announcement of Irregularity (2024/03/29) |
TPEx measures adopted (2024/03/29) |
With warrants | Can be shorted or margined? | Detail | |||||
Normal | N | N | N | N | Y | Today | History |
Financial Reports | |||||
---|---|---|---|---|---|
Cash Flows | Items | ||||
Amount (NT$ thousand) |
|||||
Cash flows from operating activities | |||||
Cash flows from investing activities | |||||
Cash flows from financing activities | |||||
Balance Sheets |
Current assets | ||||
Non-current assets | |||||
Total assets | |||||
Current liabilities | |||||
Non-current liabilities | |||||
Total liabilities | |||||
Share capital | |||||
Capital surplus | |||||
Retained earnings | |||||
Other equity interest | |||||
Treasury shares | |||||
Total equity attributable to owners of parent | |||||
Non-controlling interests | |||||
Total equity | |||||
Book Value per share(NT$) | |||||
Comprehensive Income | Operating revenue | ||||
Operating costs | |||||
Gross profit from operations | |||||
Operating expenses | |||||
Net other income (expenses) | |||||
Net operating income | |||||
Non-operating income and expenses | |||||
Profit before tax | |||||
Tax expense | |||||
Profit from continuing operations | |||||
Profit from discontinued operations | |||||
Profit | |||||
Other comprehensive income | |||||
Comprehensive income | |||||
Basic earnings per share |
Auditor's report on latest financial statements: auditor's report: |
More detail:MOPS。 |
Foreign issuers’ information is disclosed in consolidated statements. |